{
  "nctId": "NCT06268990",
  "briefTitle": "FMT in Obesity: RYGB vs. LEAN vs. Autologous FMT",
  "officialTitle": "Metabolic Outcome of Obese Subjects Receiving Fecal Microbiota Transplantation of Lean Versus Gastric Bypass Treated Subjects. A Pilot Study",
  "protocolDocument": {
    "nctId": "NCT06268990",
    "filename": "Prot_SAP_000.pdf",
    "label": "Study Protocol and Statistical Analysis Plan",
    "date": "2021-05-14",
    "uploadDate": "2024-01-29T10:24",
    "size": 651727,
    "downloadUrl": "https://clinicaltrials.gov/api/v2/studies/NCT06268990/document/Prot_SAP_000.pdf",
    "hasProtocol": true,
    "hasSap": true,
    "hasIcf": false
  },
  "phase": [
    "NA"
  ],
  "studyType": "INTERVENTIONAL",
  "allocation": "RANDOMIZED",
  "interventionModel": "PARALLEL",
  "masking": "QUADRUPLE",
  "enrollmentInfo": {
    "enrollmentCount": 30,
    "enrollmentType": "ESTIMATED"
  },
  "timeline": {
    "startDate": "2023-01-01",
    "completionDate": "2025-12-31",
    "primaryCompletionDate": "2025-12-31",
    "firstSubmitDate": "2024-01-29",
    "firstPostDate": "2024-02-21"
  },
  "eligibilityCriteria": {
    "criteria": "Inclusion Criteria:\n\n\\- Inclusion criteria for patients\n\n* Age \\>18 years\n* Morbid obesity defined by a BMI ≥ 40 kg/m2\n* Prediabetes or diabetes with HbA1C between ≥ 5.7 % OR\n* Fasting plasma glucose \\> 5.6 mmol/l (\\> 100 mg/dl) (no caloric intake for at least 8 hours) OR\n* Random plasma glucose \\> 11.1 mmol/l (\\> 200 mg/dl)\n* Informed consent\n\nInclusion criteria for RYGB-FMT intervention donors\n\n* Sustained total weight loss of ≥30% ≥12 months after RYGB surgery\n* HbA1c \\< 6.5% without insulin treatment or oral antidiabetic medication\n* Age \\>18 years\n* Informed consent\n\nInclusion criteria for LEAN-FMT intervention donors\n\n* Normal weight (BMI ≥ 20 to \\< 25 \\>18 years\n* Informed consent\n\nExclusion Criteria:\n\nExclusion criteria for patients\n\n• Non-Compliance\n\n* Insulin dependent diabetes mellitus, treated with GLP-1 agonists or poorly controlled on oral antidiabetic medications (HbA1C \\> 8%)\n* Use of any weight loss medication or participation in a weight loss program\n* History of recent body weight change (defined as body weight loss or body weight gain of ≥ 5 kg within the two months preceding study enrolment).\n* Use of immunosuppressive medication or immune modulators (glucocorticoids, methotrexate, tacrolimus, cyclosporine, thalidomide, interleukin-10 or -11) within the last three months preceding study enrolment.\n* Congenital or acquired immunodeficiencies.\n* Anatomical reconstruction of the nutrient passage (i.e. hemicolectomy, resection of small bowel, gastrectomy, sleeve gastrectomy, gastric bypass surgery, biliopancreatic diversion, fundoplication etc) or cholecystectomy.\n* Chronic diarrhoea\n* History of serious chronic disease including malignancy, rheumatic heart disease, endocarditis, or valvular disease (due to risk of bacteremia)\n* Any condition, based on clinical judgment that may make study participation unsafe\n* Pregnancy or Breast Feeding\n\nExclusion criteria for RYGB-FMT intervention donors\n\n* Intake of pre-, pro- or antibiotics within \\< 3 months before study entry\n* Use of immunosuppressive medication or immune modulators (glucocorticoids, methotrexate, tacrolimus, cyclosporine, thalidomide, interleukin-10 or -11) within the last three months preceding study enrolment.\n* Congenital or acquired immunodeficiencies.\n* Chronic or acute infectious diseases (specified under 6.2.1)\n* Drug abuse\n* Anatomical reconstruction of the nutrient passage other than surgical RYGB configuration (i.e. hemicolectomy, resection of small bowel, fundoplication, LSG-to-RYGB transformation etc) or cholecystectomy.\n* History of recent body weight change (defined as body weight loss or body weight gain of ≥ 5 kg within the two months preceding study enrolment).\n* Chronic diarrhoea or steatorrhea or acute gastrointestinal infection within ≤ 3 months before study entry.\n* History of serious chronic disease including malignancy, chronic kidney disease (eGFR \\< 60 ml/min), heart failure (NYHA ≥ III).\n* Any further condition, based on clinical judgment that may disqualify the candidate as an appropriate donor.\n\nExclusion Criteria for Lean-FMT Intervention Donors • History of overweight or obesity in the past (BMI \\> 25 kg/m2)\n\n• History of recent body weight change (defined as body weight loss or body weight gain of ≥ 5 kg within the two months preceding study enrolment).\n\n• HbA1C \\> 6.5% or treatment with insulin or oral anti-diabetic medication.\n\n• Use of any weight loss medication or participation in a weight loss program\n\n• Use of immunosuppressive medication or immune modulators (glucocorticoids, methotrexate, tacrolimus, cyclosporine, thalidomide, interleukin-10 or -11) within the last three months preceding study enrolment.\n\n• Congenital or acquired immunodeficiencies.\n\n• Chronic or acute infectious diseases (specified under 6.2.1)\n\n• Drug abuse\n\n• Anatomical reconstruction of the nutrient passage (i.e. hemicolectomy, resection of small bowel, fundoplication etc) or cholecystectomy.\n\n• Chronic diarrhoea or acute gastrointestinal infection within ≤ 3 months before study entry.\n\n• History of serious chronic disease including malignancy, chronic kidney disease (eGFR \\< 60 ml/min), heart failure (NYHA ≥ III).\n\n• Any further condition, based on clinical judgment that may disqualify the candidate as an appropriate donor.",
    "healthyVolunteers": true,
    "sex": "ALL",
    "minimumAge": "18 Years",
    "maximumAge": "60 Years",
    "stdAges": [
      "ADULT"
    ]
  },
  "endpoints": {
    "primary": [
      {
        "measure": "Insulin sensitivity",
        "description": "Change in insulin sensitivity after FMT compared to baseline as assessed by hyperinsulinemic-euglycemic clamp technique",
        "timeFrame": "after 6 weeks treatment"
      }
    ],
    "secondary": [
      {
        "measure": "Insulin sensitivity",
        "description": "Change in insulin sensitivity after 16-/24-week treatment compared to baseline as assessed by hyperinsulinemic-euglycemic clamp.",
        "timeFrame": "after 16/24 weeks treatment"
      },
      {
        "measure": "Glucose homeostasis",
        "description": "Change in glucose homeostasis compared to baseline as assessed by HOMA-IR model, fasting glucose level, and HbA1C value",
        "timeFrame": "after 6-/16-/24-week treatment"
      },
      {
        "measure": "Body weight",
        "description": "Change in total body weight, body mass index (BMI) and body composition after 6-/16-/24-week treatment compared to baseline as assessed by Dual-energy X-ray absorptiometry, DXA)",
        "timeFrame": "after 6-/16-/24-week treatment"
      },
      {
        "measure": "Blood pressure",
        "description": "Change in blood pressure and antihypertensive medication compared to baseline.",
        "timeFrame": "after 6-/16-/24-week treatment"
      },
      {
        "measure": "Fasting lipid profile",
        "description": "Change in fasting lipid profile compared to baseline.",
        "timeFrame": "after 6-/16-/24-week treatment"
      },
      {
        "measure": "Fasting blood liver enzyme levels",
        "description": "Change in fasting blood liver enzyme levels and liver fat content (assessed by CAP values with the XL probe) compared to baseline",
        "timeFrame": "after 6-/16-/24-week treatment"
      },
      {
        "measure": "Dietary intake levels",
        "description": "Change in dietary intake assessed using MyFitnessPal compared to baseline.",
        "timeFrame": "after 6-/16-/24-week treatment"
      },
      {
        "measure": "Metabolic inflammation",
        "description": "Change in metabolic inflammation and endotoxemia as assessed by circulating pro-inflammatory cytokines (TNF-a, IL-6, IL-1ß) and bacterial endotoxins (lipopolysachharide (LPS), LPS-binding protein) compared to baseline",
        "timeFrame": "after 6-/16-/24-week treatment"
      },
      {
        "measure": "Gut hormones",
        "description": "Change in postprandial release of gut hormones (PYY, GLP-1, GIP, ghrelin, CCK), insulin and bacterial metabolites (SCFA, Bile acids) before (fasting condition) and during a standardized mixed meal test (MMT) (Fresubin 200ml, 400kcal) compared to baseline",
        "timeFrame": "after 6-/16-/24-week treatment"
      },
      {
        "measure": "Hunger and Satiety Scores",
        "description": "Change in Hunger and Satiety Scores assessed via visual analog scales during the MMT",
        "timeFrame": "daily"
      },
      {
        "measure": "Fecal microbiota composition",
        "description": "Change in diversity and composition of the fecal microbiota as assessed by 16S rRNA gene profiling compared to baseline",
        "timeFrame": "after 6-/16-/24-week treatment"
      },
      {
        "measure": "Health-related quality of life",
        "description": "Change in health-related quality of life and behavior as assessed by established self-report questionnaires compared to baseline measuring: (a) eating behavior including trait food craving (FCQ-T-r), hedonic eating (PFS), restrained eating, overeating, and binge eating (EDE-Q), and emotional eating as well as disinhibition (EI); (b) personality factors such as impulsivity (BIS-15) and reward sensitivity (BIS/BAS); (c) mental and physical health, including depression, anxiety, and substance use (PHQ-D), attention-deficit/hyperactivity disorder (ASRS), and quality of life (EQ-5D). All these questionnaires have established reliability and validity.",
        "timeFrame": "after 6-/16-/24-week treatment"
      },
      {
        "measure": "Tolerability of repeated FMT",
        "description": "Safety and tolerability of repeated FMT assessed by review of adverse event diary card",
        "timeFrame": "daily"
      }
    ],
    "other": []
  },
  "complexityMetrics": {
    "eligibilityCriteria": {
      "inclusionCount": 1,
      "exclusionCount": 1,
      "totalCount": 2
    },
    "endpoints": {
      "primaryCount": 1,
      "secondaryCount": 13,
      "otherCount": 0,
      "totalCount": 14
    },
    "studyDesign": {
      "phases": [
        "NA"
      ],
      "isRandomized": true,
      "isMasked": true,
      "interventionModel": "PARALLEL"
    },
    "overallComplexityScore": 100,
    "complexityCategory": "Highly Complex"
  },
  "collectionDate": "2025-09-22T02:30:59.341Z",
  "dataSource": "ClinicalTrials.gov API v2 - Comprehensive Collection"
}